

Substitution for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>	<p style="text-align: center;">Complete if Known</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>Application Number</td> <td>09/441,140</td> </tr> <tr> <td>Filing Date</td> <td>November 16, 1999</td> </tr> <tr> <td>First Named Inventor</td> <td>Beka SOLOMON</td> </tr> <tr> <td>Group Art Unit</td> <td>4642 1647</td> </tr> <tr> <td>Examiner Name</td> <td>G. Bansa NICHOLS</td> </tr> <tr> <td>Attorney Docket Number</td> <td>SOLOMON=1R</td> </tr> </table>	Application Number	09/441,140	Filing Date	November 16, 1999	First Named Inventor	Beka SOLOMON	Group Art Unit	4642 1647	Examiner Name	G. Bansa NICHOLS	Attorney Docket Number	SOLOMON=1R
Application Number	09/441,140												
Filing Date	November 16, 1999												
First Named Inventor	Beka SOLOMON												
Group Art Unit	4642 1647												
Examiner Name	G. Bansa NICHOLS												
Attorney Docket Number	SOLOMON=1R												
Sheet 1 of 2													

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CSJ	AA	5,786,180		König et al	07-28-1998	

RECEIVED
 MAR 06 2002
 TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ⁵ (if known)				
CSJ	AB	EP	0 613 007	A3	Brems et al	08-31-1994		

Examiner Signature		Date Considered	7/30/2003
--------------------	--	-----------------	-----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449 PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/441,140
		Filing Date	November 16, 1999
		First Named Inventor	Beka SOLOMON
		Group Art Unit	1642 1647
		Examiner Name	G. Bernal NICHOLS
		Attorney Docket Number	SOLOMON=1R
Sheet	2	of	2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CS	AC	FRIEDLAND et al, "Development of an Anti-A β Monoclonal Antibody for In Vivo Imaging of Amyloid Angiopathy in Alzheimer's Disease", <u>Mol Neurobiol</u> 9(1-3):107-113 (1994)	
CS	AD	WALKER et al, "Labelinig of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody", <u>J Neuropathol Exp Neurol</u> 53(4):377-383 (1994)	

Examiner Signature		Date Considered	7/30/03
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/441,140
		Filing Date	November 16, 1999
		First Named Inventor	Beka SOLOMON
		Group Art Unit	4642 1647
		Examiner Name	G. Bancal NICHOLS
Sheet 1 of 2	Attorney Docket Number	SOLOMON=1R	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CSO	AE	5,750,349	A	Suzuki et al	05-12-1998	
	AF	5,753,624	A	McMichael et al	05-19-1998	
	AG	5,851,996	A	Kline	12-22-1998	
CSO	AH	5,955,317	A	Suzuki et al	09-21-1999	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number			
CSO	AI	WO	95/31996	A1	MILKHAUS LABORATORY	11-30-1995


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CSO	AJ	DELIMASTRO et al, "Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration", <u>Vaccine</u> 15(11):1276-1285 (1997)	
	AK	DODART et al, "Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model", <u>Nat Neurosci</u> 5(5):452-457 (2002) (published online April 8, 2002, pp. 1-6)	
	AL	JANUS et al, "Aβ peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease", <u>Nature</u> 408(6815):979-982 (2000)	
	AM	MANOUTCHARIAN et al, "Phage Displayed Biomolecules As Preventive and Therapeutic Agents", <u>Curr Pharm Biotechnol</u> 2(3):217-223 (2001)	
	AN	MORGAN et al, "Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease" <u>Nature</u> 408(6815):982-985 (2000)	
	AO	SEUBERT et al, "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids", <u>Nature</u> 359(6393):325-327 (1992)	
	AP	Elan Internet Press Release, "Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1792", January 18, 2002 (www.elan.com/NewsRoom)	
CSO	AQ	Elan Internet Press Release, "Elan and Wyeth provide update on status of Alzheimer's collaboration", March 2002 (www.elan.com/NewsRoom)	

RECEIVED
 TECH CENTER 600/2900
 AUG 28 2002

Examiner Signature	<i>G. Nichols</i>	Date Considered	7/30/02
--------------------	-------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1042 1647
Examiner Name	S. Unger NICHOLS
Attorney Docket Number	SOLOMON=1R


U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
SP	AR	6,417,178	B1	Klunk et al	07-09-2002	
	AS	6,284,221	B1	Schenk et al	09-04-2001	
	AT	6,262,335	B1	Hsiao et al	07-17-2001	
	AU	6,114,133	-	Seubert et al	09-05-2000	
	AV	5,958,883	-	Snow	09-28-1999	
	AW	5,955,079	-	Mond et al	09-21-1999	
	AX	5,877,399	-	Hsiao et al	03-02-1999	
	AY	5,869,093	-	Weiner et al	02-09-1999	
	AZ	5,869,054	-	Weiner et al	02-09-1999	
	BA	5,849,298	-	Weiner et al	12-15-1998	
	BB	5,837,473	-	Maggio et al	11-17-1998	
	BC	5,780,587	-	Potter	07-14-1998	
	BD	5,744,368	-	Goldgaber et al	04-28-1998	
	BE	5,736,142	-	Sette et al	04-07-1998	
	BF	5,733,547	-	Weiner et al	03-31-1998	
	BG	5,679,348	-	Nesburn et al	10-21-1997	
	BH	5,645,820	-	Hafler et al	07-08-1997	
	BI	5,641,474	-	Hafler et al	06-24-1997	
	BJ	5,641,473	-	Hafler et al	06-24-1997	
	BK	5,612,486	-	McConlogue et al	03-18-1997	
	BL	5,605,811	-	Seubert et al	02-25-1997	
	BM	5,585,100	-	Mond et al	12-17-1997	
	BN	5,571,500	-	Hafler et al	11-05-1996	
	BO	5,571,499	-	Hafler et al	11-05-1996	
	BP	5,441,870	-	Seubert et al	08-15-1995	
	BQ	5,434,170	-	Andrulis, Jr.	07-18-1995	
	BR	5,387,742	-	Cordell	02-07-1995	
	BS	5,270,165	-	Van Nostrand et al	12-14-1993	
BT	5,231,170	-	Averback	07-27-1993		
BU	5,231,000	-	Majocha et al	07-27-1993		
BV	5,220,013	-	Ponte et al	06-15-1993		
BW	5,208,036	-	Eppstein et al	05-04-1993		
BX	5,192,753	-	McGeer et al	03-09-1993		
BY	5,187,153	-	Cordell et al	03-09-1993		
BZ	5,057,540	-	Kensil et al	10-15-1991		
CA	5,004,697	-	Pardridge	04-20-1991		
CB	4,666,829	-	Glenner et al	05-19-1987		

RECEIVED
 NOV 15 2002
 TECH CENTER 600/2000

Examiner Signature: *[Signature]* Date Considered: 7/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2

of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1042 1647
Examiner Name	S. Unger NICHOLS
Attorney Docket Number	SOLOMON=1R

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number		Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number					
CC	WO		94/28412	A1	The Miriam Hospital	12-08-1994		
CD	WO		94/03615	A1	Medeva Holdings B.V.	02-17-1994		
CE	WO		94/01772	A1	Children's Med. Cen. Corp.	01-20-1994		
CF	EP		0 276 723	B1	Bayer AG	12-08-1993		Yes
CG	WO		93/21950	A1	Medeva Holdings B.V.	11-11-1993		
CH	WO		93/16724	A1	Autoimmune, Inc.	09-02-1993		
CI	WO		93/15760	A1	Mond et al	08-19-1993		
CJ	WO		93/14200	A1	TSI Corporation	07-22-1993		
CK	WO		93/04194	A1	Regents of U. of Minn.	03-04-1993		
CL	WO		93/02189	A1	Regents of U. of Cal.	02-04-1993		
CM	WO		92/13069	A1	Imp. Col. of Sci, Tech. & Med.	08-06-1992		
CN	WO		92/06708	A1	Brigham and Women's Hosp.	04-30-1992		
CO	WO		92/06187	A1	The Upjohn Company	04-16-1992		
CP	WO		91/19810	A1	California Biotechnology Inc.	12-26-1991		
CQ	WO		91/16819	A1	Molecular Rx, Inc.	11-14-1991		
CR	EP		0 451 700	A1	Miles Inc.	10-16-1991		
CS	WO		91/12816	A1	Autoimmune, Inc.	09-05-1991		
CT	WO		91/08760	A1	Brigham and Women's Hosp.	06-27-1991		
CU	WO		90/12871	A1	Res. Found. Mental Hygiene, Inc.	11-01-1990		
CV	WO		90/12870	A1	Res. Found. Mental Hygiene, Inc.	11-01-1990		
CW	GB		2 220 211	A	Ribi Immunochem Research Inc.	01-04-1990		
CX	WO		89/06689	A1	McLean Hosp. Corp. & U. Roch.	07-27-1989		
CY	WO		89/06242	A1	McLean Hosp. Corp. & U. Roch.	07-13-1989		
CZ	WO		89/03687	A1	Genetics Institute, Inc.	05-05-1989		
DA	WO		89/01343	A1	Regents of U. of Cal.	02-23-1989		
DB	WO		88/10120	A1	Brigham and Women's Hosp.	12-29-1988		

RECD IN MAIL NOV 15 2002
 TECH CENTER 1000/2000


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
DC		BARROW et al, "Solution Conformations and Aggregational Properties of Synthetic Amyloid β -Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" <i>J Mol Biol</i> 225(4):1075-1093 (1992)	

Examiner Signature	<i>G. Miller</i>	Date Considered	1/30/03
--------------------	------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	4642 1647
Examiner Name	S. Ungar DICHOLS
Attorney Docket Number	SOLOMON=1R

TECH CENTER 1300/2100
NOV 15 2002


RECEIVED

DD	BAUER et al, "Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Lett</u> 285(1):111-114 (1991)
DE	BICKEL et al, "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <u>Soc for Neuroscience Abstracts</u> 18:764 (325.6) (1992)
DF	BODMER et al, "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem Biophys Res Comm</u> 171(2):890-897 (1990)
DG	BORIS-LAWRIE et al, "Recent advances in retrovirus vector technology," <u>Curr Opin Genet Dev</u> 3(1):102-109 (1993)
DH	BRICE et al, "Absence of the amyloid precursor protein gene mutation (APP717: Val->Ile) in 85 cases of early onset Alzheimer's disease," <u>J Neurol Neurosurg Psychiatry</u> 56:112-113 (1993)
DI	CAPUTO et al, "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin Neuropharm</u> 15(S1):414A-415A (1992)
DJ	CHAO et al, "Transforming Growth Factor-β Protects Human Neurons Against β-Amyloid-Induced Injury," 23 rd Annual Meeting, Washington, DC, November 7-12, 1993, <u>Soc Neurosci Abstracts</u> 19:513.7 (1993)
DK	CHEN et al "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neurosci Lett</u> 125(2):223-226 (1991)
DL	CORDELL B "β-Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>An. Rev Pharmacol Toxicol</u> 34:69-89 (1994)
DM	COSTA et al, "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand J Immunol</u> 38:177-182 (1993)
DN	ELIZAN et al, "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J Neurol Sci</u> 59(3):341-347 (1983)
DO	FELSENSTEIN et al, "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neurosci Lett</u> 152:185-189 (1993)
DP	FISHER et al, "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>Proc Natl Acad Sci</u> 88:1779-1782 (1991)
DQ	GANDY et al, "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> 13:108-113 (1992)

Examiner Signature	<i>[Signature]</i>	Date Considered	7/30/03
--------------------	--------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



RECEIVED NOV 15 2002 TECH CENTER 1600


Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/441,140
		Filing Date	November 16, 1999
		First Named Inventor	Beka SOLOMON
		Group Art Unit	1642-1677
		Examiner Name	S. Ugar NICHOLS
		Attorney Docket Number	SOLOMON=1R
Sheet	4	of	8

DR	GARDELLA et al, "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem Biophys Res Comm</u> 173:1292-1298 (1990)
DS	GASKIN et al, "Human antibodies reactive with β -amyloid protein in Alzheimer's disease," <u>J Exp Med</u> 177:1181-1186 (1993)
DT	GLENNER et al, "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochem Biophys Res Comm</u> 122(3):885-890 (1984)
DU	GLENNER et al, "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochem Biophys Res Comm</u> 122(3): 1131-1135 (1984)
DV	GOATE et al, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> 349:704-706 (1991)
DW	GORTNER, <u>Outlines of Biochemistry</u> , 3 rd Ed, Gorner et al Eds., John Wiley & Sons, Inc New York, pp. 322-323, (1949)
DX	HAASS et al "Amyloid β -peptide is produced by cultured cells during normal metabolism," <u>Nature</u> 359(6393):322-5 (1992)
DY	HAGA et al, "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Res</u> 601:88-94 (1993)
DZ	HARRINGTON et al, "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β /A4-protein," <u>Biochim Biophys Acta</u> 1158(2):120-128 (1993)
EA	HAZAMA et al, "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of <i>Escherichia Coli</i> Heat-Labile Enterotoxin and Interleukin-2," <u>Immunology</u> 78:643-649 (1993)
EB	HILBICH et al, "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur J Biochem</u> 201:61-69 (1991)
EC	HUBERMAN et al, "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J Neuroimmunol</u> 52(2):147-152 (1994)
ED	IKEDA et al, "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <u>Lab Invest</u> 57(4):446-449 (1987)
EE	ITAGAKI et al, "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J Neuroimmunol</u> 24:173-182 (1989)

Examiner Signature		Date Considered	7/30/03
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



RECEIVED
 NOV 16 2003
 TECH CENTER 1111


Substitute for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>		Complete if Known	
	Application Number	09/441,140	
	Filing Date	November 16, 1999	
	First Named Inventor	Beka SOLOMON	
	Group Art Unit	1042-1647	
	Examiner Name	S. Ungar - NICHOLS	
Sheet	5	.of	8
	Attorney Docket Number	SOLOMON=1R	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
[Handwritten vertical line with arrow pointing down]	EF	WATSUBO et al, "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," <u>Neuron</u> 13:45-53 (1994)	
	EG	JANSEN et al, "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immunol Rev</u> 62:185-216 (1982)	
	EH	JOACHIM et al, "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am J Pathol</u> 138(2):373-384 (1991)	
	EI	KALARIA RN, "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res Immunol</u> 143:637-641 (1992)	
	EJ	KAWABATA et al, "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> 354:476-478 (1991)	
	EK	LAMPERT-ETCHELLS et al, "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993)	
	EL	LANGER, "New Methods of Drug Delivery," <u>Science</u> 249:1527-1532 (1990)	
	EM	LANNFELT et al, "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behav Brain Res</u> 57(2):207-213 (1993)	
	EN	LOPEZ et al, "Serum auto-antibodies in Alzheimer's disease," <u>Acta Neurol Scand</u> 84(5):441-444 (1991)	
	EO	MAJOCHA et al, "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vivo Imaging of Amyloid Angiopathy," <u>J Nuc Med</u> 33:2184-2189 (1992)	
	EP	MAK et al, "Polyclonals to β-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Res</u> 667:138-142 (1994)	
	EQ	MASTERS et al, "Amyloid plaque core protein in Alzheimer disease and Down syndrome," <u>Proc Natl Acad Sci USA</u> 82:4245-4249 (1985)	

Examiner Signature 	Date Considered 7/30/03
------------------------	----------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/441,140
		Filing Date	November 16, 1999
		First Named Inventor	Beka SOLOMON
		Group Art Unit	1642 <i>667</i>
		Examiner Name	S. Ungar <i>NICHOLS</i>
		Attorney Docket Number	SOLOMON=1R
Sheet	6	of	8

RECEIVED NOV 16 2002


RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<div style="font-size: 2em; font-family: cursive;">EBO</div> <div style="font-size: 4em; font-family: cursive;"> </div> <div style="font-size: 2em; font-family: cursive;">EBO</div>	ER	McGEER et al, "Immunohistochemical Localization of Beta-Amyloid Precursor Protein Sequences in Alzheimer and Normal Brain Tissue by Light and Electron Microscopy," <u>J Neurosci Res</u> 31:428-442 (1992)	
	ES	MILLER et al, "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J Exp Med</u> 174:791-798 (1991)	
	ET	MORI et al, "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J Biol Chem</u> 267(24):17082-17088 (1992)	
	EU	MORRIS et al, "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)," <u>Neurology</u> 39:1159-1165 (1989)	
	EV	MURPHY et al, "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am J Pathol</u> 144(5):1082-1088 (1994)	
	EW	NEWCOMBE et al, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim Biophys Acta</u> 104:480-486 (1965)	
	EX	PARDRIDGE et al, "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem Biophys Res Comm</u> 146:307-313 (1987)	
	EY	PRIEELS et al, "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994)	
	EZ	QUON et al, "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> 352:239-241 (1991)	
	FA	ROGERS et al, "Complement activation by β -amyloid in Alzheimer Disease," <u>Proc Natl Acad Sci USA</u> , 89:1-5 (1992)	
	FB	ROSSOR et al, "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Ann of NY Acad Sci</u> , 695:198-202 (1993)	
	FC	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976)	

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>7/30/03</i>
--------------------	--------------------	-----------------	----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/441,140
		Filing Date	November 16, 1999
		First Named Inventor	Beka SOLOMON
		Group Art Unit	1842 Koff
		Examiner Name	S. Ungar NICHOLS
		Attorney Docket Number	SOLOMON=1R
Sheet	7	of	8

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<div style="font-size: 2em; font-weight: bold;">}</div>	FD	SAIDO et al, "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J Biol Chem</u> 269(21):15253-15257 (1994)	
	FE	SAIDO et al, "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J Biol Chem</u> 268(33):25239-25243 (1993)	
	FF	SAITOH et al, "Immunological Analysis of Alzheimer's Disease Using Anti- β -protein Monoclonal Antibodies," <u>Sapporo Med J</u> 60:309-320 (1991)	
	FG	SELKOE DJ "Alzheimer's Disease: A Central Role for Amyloid," <u>J Neuropathol Exp Neurol</u> 53(5): 438-447 (1994)	
	FH	SELKOE DJ, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends Neurosci</u> , 16(10):403-409 (1993)	
	FI	SELKOE DJ, "Alzheimer's disease. In the Beginning...", <u>Nature</u> 354(6353):432-433 (1991)	
	FJ	SELKOE DJ, "Amyloid Protein and Alzheimer's Disease," <u>Sci Am</u> 265(5):68-78 (1991)	
	FK	SELKOE DJ, "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> 6(4):487-498 (1991)	
	FL	SHIOSAKA S "Attempts to make models for Alzheimer's disease," <u>Neurosci Res</u> 13(4):237-255 (1992)	
	FM	TRIEB et al, "Is Alzheimer β amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37 (1994)	
	FN	VAN GOOL et al, "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neurosci Lett</u> 172:122-124 (1994)	
	FO	VERBEEK et al, "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Am J Pathol</u> 144(1):104-116 (1994)	


TECH CENTER 1600/2910
 NOV 15 2002

RECEIVED

Examiner Signature		Date Considered	7/30/03
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/441,140
		Filing Date	November 16, 1999
		First Named Inventor	Beka SOLOMON
		Group Art Unit	1642 1647
		Examiner Name	S. Ungar NICHOLS
		Attorney Docket Number	SOLOMON=1R
Sheet 8	of 8		

SO	FP	WEINER et al, "Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu Rev Immunol</u> 12:809-837 (1994)	/
↓	FQ	WONG et al, "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>Proc Natl Acad Sci USA</u> 82:8729-8732 (1985)	/
	FR	<u>New York Times National</u> , "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94)	/
	FS	Wisconsin Alumni Research Foundation, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep 70(24), 56. (June 19, 1969)	/
SW	FT	Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (1969)	/

RECEIVED
 NOV 15 2002
 TECH CENTER 1600/2900

Examiner Signature		Date Considered	7/30/03
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.